Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Fig. 4

Percentage changes in TG and HDL-C levels. Baseline levels indicate mean ± SD, and bars indicate LS mean percentage change (95 % CI) from baseline to Week 12 (LOCF). *** p < 0.001 vs. placebo (ANCOVA with baseline value as covariate). TG triglyceride, HDL-C high-density lipoprotein cholesterol, SD standard deviation, LS least squares, CI confidence interval, LOCF last observation carried forward, ANCOVA analysis of covariance

Back to article page